Heading to Germany? The European Society for Medical Oncology is the leading European professional organisation for medical oncology. The ESMO...
Exclusive partner of Caris Molecular Intelligence in Australia and New Zealand. 
News
New research reveals certain mutations detected by plasma genotyping in NSCLC patients due to clonal haematopoiesis, not tumour
The large amount of enthusiasm behind the potential applications of plasma cell-free DNA (cfDNA) analysis appears to have outpaced our...
New research highlights superior clinical benefit and lower utility cost of Caris Molecular Intelligence
New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 4th-8th November 2017 in Glasgow, Scotland...
New research compares Caris Molecular Intelligence and Foundation One-guided treatment costs
New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting from 4th-8th November 2017 in Glasgow,...
New research from ESMO highlights clinical benefit of Caris Molecular Intelligence
The progression-free survival (PFS) of patients with heavily pre-treated rare or refractory cancer usually declines with every new line of...
NICE briefing on Caris Molecular Intelligence
The National Institute for Health and Care Excellence (NICE) has released a medical technology innovation briefing on Caris Molecular Intelligence...
Molecular profiling explained by Dr David Spetzler: An interview
NH: Hello and thank you for tuning into the program. I’m your host Neil Howard here on Health Professional Radio....
Guardant Health files lawsuit against Foundation Medicine
An original complaint against Foundation Medicine Inc. has recently been filed by Guardant Health Inc. Guardant seeks to recover damages and...
First results from the AURORA pilot study for molecular screening of patients with advanced breast cancer
In April 2014, OncoDNA, a clinical NGS provider affiliated with the Institute of Pathology and Genetics in Gosselies, Belgium, announced...
Measuring prevalence of oncogenic homologous recombination pathway mutations across 53,000 tumours
Results of a molecular profiling analysis to identify the frequency of Homologous Recombination Deficiencies (HRD) from approximately 53,000 tumours have...
Molecularly identifying candidates for the NCI-MATCH clinical trial
Caris Life Sciences® has announced a collaboration with the National Cancer Institute (NCI) for the NCI-Molecular Analysis for Therapy Choice...
Identifying patients with MSI-high (or mismatch repair deficient) solid tumours more likely to respond to immunotherapy
The primary objective of this study was to estimate the efficacy of the immunotherapy drug pembrolizumab in patients with MSI-High...
- 1
- 2
Created: February 9, 2017 - Modified: June 28, 2019